| Acceptance and Commitment Therapy vs. Supportive Psychotherapy With Cystic Fibrosis Patients (NCT04114227) | Thomas Jefferson University | 2019-07-01 |
| PREMO Study: to Investigate Port REMoval Outcomes (NCT03948958) | Universitaire Ziekenhuizen KU Leuven | 2019-06-28 |
| Phase 2 Combination Study With Escalating Doses of MS1819-SD on Top of a Stable Dose of PPEs (NCT04302662) | AzurRx SAS | 2019-06-27 |
| PK/PD of Vitamin D3 in Adults With CF (NCT03734744) | University of Southern California | 2019-06-17 |
| DPI-Tobra-Kind Cyclops® in Children With Cystic Fibrosis (NCT03485456) | University Medical Center Groningen | 2019-05-29 |
| A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis (NCT04010799) | Chiesi Farmaceutici S.p.A. | 2019-05-27 |
| HFNT During Exercise in CF (NCT03965832) | The Leeds Teaching Hospitals NHS Trust | 2019-05-24 |
| A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients with Cystic Fibrosis (NCT03822455) | AlgiPharma AS | 2019-05-16 |
| Evaluation of a Behavioural Intervention Using App Technology in CF (NCT03782909) | Sheffield Teaching Hospitals NHS Foundation Trust | 2019-05-08 |
| Improving P. Aeruginosa Detection With Breath-based Diagnostics (IMPACT-Breath) (NCT04735952) | University of British Columbia | 2019-05-03 |
| Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis (NCT03961516) | University Hospitals Cleveland Medical Center | 2019-05-01 |
| Multicenter Study of Patient-reported Gastrointestinal Symptoms in People With Cystic Fibrosis (NCT03801993) | Chris Goss | 2019-05-01 |
| A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (NCT03912233) | Vertex Pharmaceuticals Incorporated | 2019-04-30 |
| Cystic Fibrosis Reproductive and Sexual Health Collaborative: Building Online Research Partnerships (NCT04999865) | University of Washington | 2019-04-19 |
| A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis (NCT03911713) | Vertex Pharmaceuticals Incorporated | 2019-04-17 |
| Orkambi Treatment in 2 to 5 Year Old Children With CF (NCT03795363) | Children's Hospital of Philadelphia | 2019-04-10 |
| Implication of UNconventionaL T Lymphocytes in Cystic Fibrosis (UNLOCk) (NCT03886350) | University Hospital, Tours | 2019-04-03 |
| The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis (NCT03870841) | Pulmocide Ltd | 2019-04-03 |
| Bottle PEP in Cystic Fibrosis (NCT04961008) | Marmara University | 2019-04-01 |
| The Effect of a Pre-meal Snack and/or Exercise on Post-prandial Glycemic Excursions in Adults With Cystic Fibrosis (NCT03710538) | Institut de Recherches Cliniques de Montreal | 2019-04-01 |
| Epidemiology and Clinical Characteristics of Non-Tuberculous Mycobacteria Infections in Cystic Fibrosis Patients. (NCT03312075) | University Hospital, Brest | 2019-03-25 |
| Cystic Fibrosis and Fit-to-Fly (NCT03843723) | Oslo University Hospital | 2019-03-01 |
| Reaction Time and Postural Control in Individuals With Cystic Fibrosis and Bronchiectasis (NCT03902236) | Hacettepe University | 2019-03-01 |
| Mucoid Staphylococcus Aureus in Cystic Fibrosis Airways (NCT04171583) | University Hospital Muenster | 2019-03-01 |
| Psychological Study in Children With Mucoviscidosis (NCT05948488) | University Hospital, Toulouse | 2019-02-28 |
| Gastrointestinal Study at Orkambi Therapy in CF Patients (NCT03859531) | Karolinska University Hospital | 2019-02-27 |
| Intravenous Iron in Adults With Cystic Fibrosis (NCT03632525) | University of Oxford | 2019-02-22 |
| Analysis of Remote Monitoring/Virtual Clinic Data in Adult Patients With Cystic Fibrosis (Project Breathe) (NCT06222905) | Papworth Hospital NHS Foundation Trust | 2019-02-20 |
| Epidemiology of the Nasal Flora at the Reference Center for Cystic Fibrosis of Queen Fabiola Children's University Hospital. (NCT03911258) | Queen Fabiola Children's University Hospital | 2019-02-06 |
| Ivacaftor Treatment in 4 Month to 2 Year Old CF Subjects (NCT03783286) | Children's Hospital of Philadelphia | 2019-02-06 |
| Cross Transmissions of Pseudomonas Aeruginosa Between Children From a Same Cystic Fibrosis Center. (NCT03910920) | Queen Fabiola Children's University Hospital | 2019-02-06 |
| Effects of Aerobic Interval Training on Glucose Tolerance in Children and Adolescents With Cystic Fibrosis (NCT03653949) | Universidade Federal do Rio Grande do Norte | 2019-02-04 |
| Intervention in Chronic Pediatric Patients and Their Families. (NCT04476433) | University of Valencia | 2019-02-04 |
| Educational Program Through Video Conference for Inhaled Therapies in Cystic Fibrosis Patients (NCT03850145) | University Hospital, Montpellier | 2019-02-01 |
| Evaluation of Device Settings for Airway Clearance Using The Monarch Airway Clearance System (NCT03645473) | Hill-Rom | 2019-01-24 |
| Modeling of Chest Physiotherapy Using Impedance Measurements (PHYSIOMOD) (NCT04094441) | Assistance Publique - Hôpitaux de Paris | 2019-01-10 |
| Pharmacokinetics of Polymyxin B in Adult Patients With Cystic Fibrosis (NCT04335370) | University of Michigan | 2019-01-09 |
| Manuka Honey Sinus Rinse Study (NCT04589897) | Swansea University | 2019-01-07 |
| Effects of Expiratory Muscle Training on Cough Efficacy in Children and Adolescents With Cystic Fibrosis (NCT03873688) | Cigdem Emirza | 2019-01-02 |
| WGS of Korean Idiopathic Bronchiectasis (NCT03809091) | Seoul National University Hospital | 2019-01-01 |
| A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis (NCT03647228) | Ionis Pharmaceuticals, Inc. | 2018-12-13 |
| SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects (NCT03669614) | Aridis Pharmaceuticals, Inc. | 2018-12-07 |
| New Markers of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Function in Sweat (NCT03993600) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2018-12-04 |
| Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis) (NCT02323100) | National Jewish Health | 2018-12-02 |
| Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations (NCT03624101) | University of Alabama at Birmingham | 2018-12-01 |
| Continuous Cardiorespiratory Monitoring in Cystic Fibrosis (NCT04489186) | Byteflies | 2018-12-01 |
| A DDI Study of FDL169 and FDL176 in Healthy Subjects (NCT03756922) | Flatley Discovery Lab LLC | 2018-11-27 |
| Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CF (NCT03748199) | Santhera Pharmaceuticals | 2018-11-08 |
| Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults (NCT03265288) | Laurent Pharmaceuticals Inc. | 2018-11-05 |
| Project 2 Airway Potential Hydrogen (pH) in Asthma (NCT03617718) | Case Western Reserve University | 2018-11-01 |
| Validation of a Predictive Score for HAST (NCT03728595) | The Leeds Teaching Hospitals NHS Trust | 2018-10-29 |
| Non-invasive Prenatal Diagnosis of Monogenic Disorders by Linked-reads Technology (NCT03622892) | University Hospital, Brest | 2018-10-18 |
| Early Check: Expanded Screening in Newborns (NCT03655223) | RTI International | 2018-10-15 |
| Measures of Respiratory Health Registry (NCT05501587) | University of British Columbia | 2018-10-11 |
| Resting Energy Expenditure in Patients With Cystic Fibrosis: A Pilot Study (NCT03699982) | CAMC Health System | 2018-10-10 |
| Molecular Diagnosis of Respiratory Viral Infections on Sputum From Cystic Fibrosis Patients (NCT03736096) | University Hospital, Brest | 2018-10-03 |
| Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age (NCT03691779) | Vertex Pharmaceuticals Incorporated | 2018-10-02 |
| Steps Ahead: Optimising Physical Activity and Health in Adults With Cystic Fibrosis (NCT03672058) | University of Limerick | 2018-10-01 |
| Functional Respiratory Imaging and Orkambi in CF (NCT03956589) | University Hospital, Antwerp | 2018-10-01 |
| Effect of HFCWO Vests on Spirometry Measurements (NCT03628456) | International Biophysics Corporation | 2018-09-13 |
| Intestinal Inflammation in CF Patients (NCT04392544) | The Hospital for Sick Children | 2018-09-11 |
| Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del (NCT03601637) | Vertex Pharmaceuticals Incorporated | 2018-09-07 |
| Gut Imaging for Function & Transit in Cystic Fibrosis Study 1 (NCT03566550) | Nottingham University Hospitals NHS Trust | 2018-09-04 |
| Influence of a Residential Rehabilitation Program on Body Composition in Patients with Cystic Fibrosis (NCT04527796) | University Hospital, Ghent | 2018-09-01 |
| Assessment of a PERT-free Nutritional Therapeutic Delivery System for Cystic Fibrosis (NCT04966897) | GlycosBio, Inc. | 2018-08-31 |
| Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis (NCT03591094) | Proteostasis Therapeutics, Inc. | 2018-08-21 |
| A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del (NCT03625466) | Vertex Pharmaceuticals Incorporated | 2018-08-10 |
| Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI) (NCT03551691) | Children's Hospital of Philadelphia | 2018-08-07 |
| Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age (NCT03633526) | Vertex Pharmaceuticals Incorporated | 2018-08-03 |
| A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F) (NCT03525548) | Vertex Pharmaceuticals Incorporated | 2018-08-03 |
| Effects of AD on VI in Patients With CF (NCT03655249) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2018-08-01 |
| Airway Clearance Therapy on Hyperpolarized 129Xenon and MRI (NCT03593434) | Children's Hospital Medical Center, Cincinnati | 2018-07-30 |
| Efficacy of a New Sweat Collection Support: Impact on Neonatal Screening and Early Treatment of Cystic Fibrosis (NCT03913507) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2018-07-14 |
| A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy (NCT03447262) | Vertex Pharmaceuticals Incorporated | 2018-07-13 |
| Study for Evaluating the Real Use of Inhaled Aztreonam Lysine in Patients With Cystic Fibrosis (NCT03607396) | Hospital Universitari Vall d'Hebron Research Institute | 2018-07-01 |
| Lum-Iva-biota: Exploring the Respiratory Mycobiota and Microbiota Profile in French CF Patients Taking Lumacaftor-Ivacaftor (NCT03565692) | University Hospital, Bordeaux | 2018-07-01 |
| IPV vs CPT for Airway Clearance During CF Exacerbation (NCT03261219) | University of Florida | 2018-07-01 |
| Modulate-CF: Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators (NCT04732910) | Charite University, Berlin, Germany | 2018-07-01 |
| Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules (NCT03502070) | Mylan Inc. | 2018-06-26 |
| A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) (NCT03525444) | Vertex Pharmaceuticals Incorporated | 2018-06-15 |
| Neurodevelopmental Assessment of Infants With Cystic Fibrosis (NCT03577756) | Hacettepe University | 2018-06-11 |
| Telehealth Cognitive Behavioral Stress Management for Adults With Cystic Fibrosis (NCT03560726) | National Jewish Health | 2018-06-04 |
| A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis. (NCT03540524) | Lakefront Biotherapeutics NV | 2018-05-31 |
| Comparison of 129Xe MRI With 19F MRI in CF Lung Disease (NCT03482960) | University of North Carolina, Chapel Hill | 2018-05-29 |
| A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis (NCT03559062) | Vertex Pharmaceuticals Incorporated | 2018-05-17 |
| Ready to Use Therapeutic Food (RUTF) to Promote Growth in Cystic Fibrosis (NCT03462056) | Washington University School of Medicine | 2018-05-17 |
| Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis (NCT03375047) | Sanofi | 2018-05-10 |
| Evaluation of Sit-to-stand Test in Patients With Cystic Fibrosis and Matched Controls. (NCT03524859) | Universidad Católica San Antonio de Murcia | 2018-05-03 |
| CF Bronchodilation (NCT03522831) | University of British Columbia | 2018-05-01 |
| A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F) (NCT03460990) | Vertex Pharmaceuticals Incorporated | 2018-05-01 |
| A CFit Study - Acute Exercise (NCT03237767) | University of Portsmouth | 2018-05-01 |
| A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation (NCT03537651) | Vertex Pharmaceuticals Incorporated | 2018-04-25 |
| Study of Circulating Blood Cell Monocytes as Predictive Biomarker of Bone Cystic Fibrosis Disease. Impact of CFTR Correctors. (NCT03492567) | Assistance Publique - Hôpitaux de Paris | 2018-04-25 |
| Evaluating the Alimentary and Respiratory Tracts in Health and Disease (EARTH) Research Program. (NCT04071314) | The University of New South Wales | 2018-04-18 |
| A Study to Compare the Pharmacokinetics of Different Oral Formulations of FDL169 in Healthy Subjects (NCT03527095) | Flatley Discovery Lab LLC | 2018-04-05 |
| STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) (NCT03489629) | University of North Carolina, Chapel Hill | 2018-04-03 |
| Epidemiology of Anaerobic Bacteria in Cystic Fibrosis Patients: Descriptive and Non-interventional Study (NCT04879381) | University Hospital, Brest | 2018-03-29 |
| Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis (NCT03768089) | Vertex Pharmaceuticals Incorporated | 2018-03-20 |
| A Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects (NCT03516331) | Flatley Discovery Lab LLC | 2018-03-07 |
| A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) (NCT03447249) | Vertex Pharmaceuticals Incorporated | 2018-03-07 |